US1580400A - Composition for the treatment of goiter - Google Patents

Composition for the treatment of goiter Download PDF

Info

Publication number
US1580400A
US1580400A US28019A US2801925A US1580400A US 1580400 A US1580400 A US 1580400A US 28019 A US28019 A US 28019A US 2801925 A US2801925 A US 2801925A US 1580400 A US1580400 A US 1580400A
Authority
US
United States
Prior art keywords
composition
treatment
goiter
grams
iodine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US28019A
Inventor
Bommarito Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US28019A priority Critical patent/US1580400A/en
Application granted granted Critical
Publication of US1580400A publication Critical patent/US1580400A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • My invention relates to a composition, which is particularly adaptable for use in the treatment of goiter.
  • goiter is considered to be a patholo ical enlargement of the thyroid g1 nd, in which the biological cells of this glan are abnormal to such an'extent that the hysiological internal secretion of the thyroid gland in the last stages of the goiter is prevented, and in all stages, the internal secretion of the thyroid
  • a treatment which will revive the internal secretion of the gland will serve to. restore the biological cells to normal condition, decrease the enlargement,.and remove the pathological disturbance.
  • r v 4 Thedecrease of the enlar ement and the removal ofthe pathological. isturbancewill be effected by-the revival of the normal flow of the internal secretion oft-he gland, but the treatment which will revive the internal se-.
  • cretion will also directly aid the restoration of the biolo 'calcellsto normal condition.
  • the fundamental ingr edients whichare designedto aflect'the blological cel-ls'of the thyroid gland in the manner indicated, and remove the pathological disturbance are:
  • the distilled water serves as a vehicle for.
  • the glycerine also serves as a .sol-
  • tary iodine twenty centigrams
  • potassium iodide two grams
  • guaiacol four grams
  • the glycerine is set out as being pure and neutra solvent lmust be firee from any qualities
  • the composition is administered by intramuscular 1n ect1ons and on this account, the
  • the amount of the mixture which will be injected and The potassium iodide serves to assist the dissolving of the elementary iodine.
  • a composition for intra-muscular treatment-of goiter comprising the following ingredients in substantially the proportions I set-'out, to wit: elementary iodine, twenty grams; guaiacol, four grams; distilledwater, fifteen grams; pure neutral glycerine ten grams, J
  • a composition for intro-muscular treatment of goiter comprising in substantially V I the proportions set out the following ingredi- 10 e'nts, to wit: elementary iodine, twenty centigrams; potassium iodide,- two grams; guaiacol, four grams; and a vehicle suitable for intro-muscular injection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

Pate ted A r. 13,1926. v
UNITED STATES PATENT OFFlCE PAULJBOMMARITO, OF DETROIT, MICHIGAN.
' T all whom it may concern:
comrosrrron roB. THE TREATMENT or sense.
so Drawing.
Be it known that I, PA L BOMMARITO, a citizen of theUnited States, residing at Detroit, in the county of Wayne and State of Michigan, have invented a new'and useful I Improvement in a Composition for the gland is disturbed. 20.
-- Treatment of Goiter, of which the following is a specification.
My invention relates to a composition, which is particularly adaptable for use in the treatment of goiter. In medical science, goiter is considered to be a patholo ical enlargement of the thyroid g1 nd, in which the biological cells of this glan are abnormal to such an'extent that the hysiological internal secretion of the thyroid gland in the last stages of the goiter is prevented, and in all stages, the internal secretion of the thyroid It is recognized that a treatment which will revive the internal secretion of the gland, will serve to. restore the biological cells to normal condition, decrease the enlargement,.and remove the pathological disturbance. r v 4 Thedecrease of the enlar ement and the removal ofthe pathological. isturbancewill be effected by-the revival of the normal flow of the internal secretion oft-he gland, but the treatment which will revive the internal se-.
, cretion, will also directly aidthe restoration of the biolo 'calcellsto normal condition.
To provi e a composition which will produce the desired efiect, is an object of the present invention.
In the composition, the ingredients used are: Elementa iodine, potassium iodide, guaiacolgdistille water,=and glycerine.
The fundamental ingr edients whichare designedto aflect'the blological cel-ls'of the thyroid gland in the manner indicated, and remove the pathological disturbance are:
1 elementary iodine, potassium 'iodide, andguaiacol.
v j The distilled water serves as a vehicle for.
f the fundamental ingredients and asa sol:
vent. The glycerine also serves as a .sol-
vent, and tendsto reduce irritation incident to the injection of the composition and con t'rols, tolsome extent, the reactionresulting from .theinjeetion.
' .In' this description,
state.
. These ingredients preferablyfaisedfin' the follow ng prpportions, to wit: element-rh e elementary iodine referred to -is,,the p'u e. iodine"in lcrystal K iodine, potassium iodi e,'gi1aiac ol, in solution .in a vehicle suitable for intra-muscular Application filed May 4, 1925. Serial No. 28,019.
tary iodine, twenty centigrams; potassium iodide, two grams; guaiacol, four grams;
distilled water, fifteen-grams; pure neutral glycerine, ten 'ams.
It will be noted that the glycerine is set out as being pure and neutra solvent lmust be firee from any qualities The composition is administered by intramuscular 1n ect1ons and on this account, the
which would unduly irritate, or infect the person receiving the treatment. The amount of the mixture which will be injected and The potassium iodide serves to assist the dissolving of the elementary iodine.
Whether or not there is any chemical reaction between the ingredients usedg the applicant is at present unable to state. The statement is made, however, that the ingredients used have given very satisfactory results in the treatment of cases of goiter, in various "degrees of development, and the composition set out herein is the result of 8 long and frequent experiments, so that the applicant is convinced that, the three funda- -mental ingredients used are essential and that they have .a co-operative relation in their eifect on the patient treated. This conyiction has arisen from the studied results in many experiments in which one of the fundamentals was omitted and the other two combined. The ex eriments were also carried further in coni ining two of the fundaing'redieits', the result bein vmentalingredients set out-herein with other o thatthe com- I *POSltlOll set out herein-was 'scoveredj to be be the" most efl'eetive,although itwill readily appear to thoseskilied in the practiceflof '-medicine, that slightvariations 1n the proportionate amounts might be had without diminishing, to any great extent, the benefits defivedfmm use-0f the t position,
whatlclaimisz. p v
p 1. A composition for intra muscular treat ment' of goiter, com rising: elementary injection'z" '5 centigrams; potassium iodide, two
2. A composition for intra-muscular treatment-of goiter, comprising the following ingredients in substantially the proportions I set-'out, to wit: elementary iodine, twenty grams; guaiacol, four grams; distilledwater, fifteen grams; pure neutral glycerine ten grams, J
l 3. A composition for intro-muscular treatment of goiter comprising in substantially V I the proportions set out the following ingredi- 10 e'nts, to wit: elementary iodine, twenty centigrams; potassium iodide,- two grams; guaiacol, four grams; and a vehicle suitable for intro-muscular injection.
foregoing specification.
In testimony whereof, I have. signed the "k i
US28019A 1925-05-04 1925-05-04 Composition for the treatment of goiter Expired - Lifetime US1580400A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US28019A US1580400A (en) 1925-05-04 1925-05-04 Composition for the treatment of goiter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28019A US1580400A (en) 1925-05-04 1925-05-04 Composition for the treatment of goiter

Publications (1)

Publication Number Publication Date
US1580400A true US1580400A (en) 1926-04-13

Family

ID=21841096

Family Applications (1)

Application Number Title Priority Date Filing Date
US28019A Expired - Lifetime US1580400A (en) 1925-05-04 1925-05-04 Composition for the treatment of goiter

Country Status (1)

Country Link
US (1) US1580400A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297232A (en) * 1978-01-12 1981-10-27 Samuel Ruben Glycol-iodine composition and method of preparation
US5389385A (en) * 1985-07-31 1995-02-14 Ghent; William R. Treatment of iodine deficiency diseases
WO1998043481A1 (en) * 1997-04-02 1998-10-08 West Agro, Inc. Stable glycerin iodine concentrate compositions
US5910318A (en) * 1991-03-28 1999-06-08 943038 Ontario Inc. Treatment of iodine deficiency diseases
US5955101A (en) * 1991-03-28 1999-09-21 943038 Ontario Inc. Dry starch-iodine pharmaceutical formulations
US6019970A (en) * 1985-07-31 2000-02-01 Ghent William R. Treatment of iodine deficiency diseases
WO2000018237A1 (en) * 1998-09-30 2000-04-06 West Agro, Inc. Stable glycerin iodine concentrate compositions
US20100266573A1 (en) * 2007-11-23 2010-10-21 Pharmalundensis Ab Method and means for obtaining bronchorelaxation
US20100272814A1 (en) * 2007-12-19 2010-10-28 Pharmalundensis Ab Method and means for producing bronchorelaxation

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297232A (en) * 1978-01-12 1981-10-27 Samuel Ruben Glycol-iodine composition and method of preparation
US5389385A (en) * 1985-07-31 1995-02-14 Ghent; William R. Treatment of iodine deficiency diseases
US6019970A (en) * 1985-07-31 2000-02-01 Ghent William R. Treatment of iodine deficiency diseases
US5910318A (en) * 1991-03-28 1999-06-08 943038 Ontario Inc. Treatment of iodine deficiency diseases
US5955101A (en) * 1991-03-28 1999-09-21 943038 Ontario Inc. Dry starch-iodine pharmaceutical formulations
WO1998043481A1 (en) * 1997-04-02 1998-10-08 West Agro, Inc. Stable glycerin iodine concentrate compositions
US5885620A (en) * 1997-04-02 1999-03-23 West Agro, Inc. Stable glycerin iodine concentrate compositions
AU722057B2 (en) * 1997-04-02 2000-07-20 West Agro, Inc. Stable glycerin iodine concentrate compositions
WO2000018237A1 (en) * 1998-09-30 2000-04-06 West Agro, Inc. Stable glycerin iodine concentrate compositions
US20100266573A1 (en) * 2007-11-23 2010-10-21 Pharmalundensis Ab Method and means for obtaining bronchorelaxation
US20100272814A1 (en) * 2007-12-19 2010-10-28 Pharmalundensis Ab Method and means for producing bronchorelaxation

Similar Documents

Publication Publication Date Title
US1580400A (en) Composition for the treatment of goiter
Davies-Colley Slipping rib
JP2915931B2 (en) Anti-irritant and desensitizing compositions and methods of use
US2056208A (en) Acetyl-salicylic acid composition
US2001046A (en) Medicinal preparation
Edington Sickle-cell Trait and Sickle-cell Anaemia
JPS5914519B2 (en) liquid shampoo
JP3874273B2 (en) Hair treatment agent
US2361477A (en) Cosmetic or pharmaceutical product
DE616362C (en) Head massagers
US1370263A (en) Composition of matter
US1298407A (en) Salve.
DE638839C (en) Process for the production of aqueous-alcoholic cholesterol solutions
EP0021424B1 (en) Iodide containing composition for treating ocular opacity
Wrong Penicillin therapy in skin infections
US1407502A (en) Detergent
US2100781A (en) Antiseptic for the treatment of genitourinary infections
ES423697A1 (en) Haptoglobin in aqueous solution and process for tits preparation
US2221690A (en) Therapeutic composition
AT215082B (en) Corneal emollients
Kinnear The streptococcal dermatoses
DI The Whitfield tradition of therapy.
Anderson Dermatitis from grapes
US1395228A (en) Medicinal compound
DE845690C (en) Process for increasing the solubility of glycosides of the sex hormones and cardiac agents from the cyclopentanoperhydrophenanthrene series